Elorsa, Dapmie C.
HRN: 24-54-83 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/09/2024
CLINDAMYCIN 150MG/ML, 4ML (AMP)
02/09/2024
02/16/2024
IV
600mg
Q6
Cellulitis, Right Foot
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes